Iralukast Novartis AG.
Iralukast is an LTD4 and LTE4 antagonist under development by Novartis and in phase II clinical trials as a potential treatment for asthma [244117], [177071]. In a double-blind, placebo-controlled trial in 16 patients with mild to moderate asthma, a single 1.5 mg inhaled dose of iralukast reduced the incidence of exercise-induced bronchiospasm and was well-tolerated [272161]. Novartis has an agreement with Rhone-Poulenc Rorer to use its Ultrahaler delivery system for iralukast and phase II trials are underway [220836]. The agreement also involves the development of further related compounds and delivery systems.